First look at the new 2026 - 2027 Covid Vaccines
[media=https://www.youtube.com/watch?v=O6vo2sKiPUk]
The 2026–2027 COVID vaccine uses an XFG‑based spike protein sequence selected by FDA VRBPAC due to its strong neutralizing performance across circulating JN.1‑lineage variants. The vaccine trains B‑cells and T‑cells to recognize the updated spike antigen, improving immune protection against expected fall/winter SARS‑CoV‑2 strains.
The 2026–2027 COVID vaccine uses an XFG‑based spike protein sequence selected by FDA VRBPAC due to its strong neutralizing performance across circulating JN.1‑lineage variants. The vaccine trains B‑cells and T‑cells to recognize the updated spike antigen, improving immune protection against expected fall/winter SARS‑CoV‑2 strains.
